Verapamil is a competitive inhibitor of gamma-aminobutyric acid and calcium uptakes by mouse brain subcellular particles.
We found that verapamil and its methoxy analogue, D600, were relatively potent (micromolar) inhibitors of Na+-dependent GABA uptake by a mouse brain microsomal subfraction (P3). Verapamil was competitive with GABA and uncompetitive with Na+ in the uptake assay with the P3 fraction. These substances were much less effective in inhibiting GABA binding in a receptor-related assay system with synaptosomal membranes. Inhibition by verapamil of Na+-dependent 45Ca++ uptake by the P3 particles was competitive with Ca++. A consideration of our results with those in the literature led to the suggestion that the interaction of verapamil and related substances with GABA and 45Ca uptake processes by the P3 fraction, as well as with many other membrane activities, may be allosteric in nature rather than directly competitive with specific ligands at their binding sites.
D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D005711:Gallopamil / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D012964:Sodium / Q000378:metabolism; D013574:Synaptosomes / Q000378:metabolism; D014700:Verapamil / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D005711:Gallopamil; D005680:gamma-Aminobutyric Acid; D012964:Sodium; D014700:Verapamil; D002118:Calcium